联合化疗治疗卵巢癌

 
一项大型临床试验结果显示，通过腹腔进行化疗能够将晚期卵巢癌患者的生存时间延长大约1年。

研究人员将新近诊断的III期卵巢癌患者随机分成两组:接受静脉化疗，或者接受静脉和腹腔内导管插入化疗。 这项为期7年涉及400例患者的研究结果，发表在2006年1月5日《新英格兰期刊》之上。

但是接受腹腔化疗患者的副作用，包括血细胞计数减少和神经系统疾病显著增多，在治疗期间的生活质量明显较差。需要接受支持治疗或者出现手术并发症、肾功能不全、或者左侧结肠切除的患者，都不适合腹腔内化疗。205例入选患者之中只有86例能够完成腹腔化疗。

Combined Drug Method Best for Ovarian Cancer
 
A large clinical trial has shown that chemotherapy delivered into the abdomen increases survival in some women with advanced ovarian cancer by about one year.

The investigators randomly grouped women with newly diagnosed stage III ovarian cancer into two categories: those who would get all chemotherapy intravenously or those who would get chemotherapy both intravenously and intraperitoneal (IP) through a catheter inserted directly into the abdomen. The results, from a seven-year study of more than 400 patients, were reported in the January 5, 2006, issue of The New England Journal of Medicine.

However, side effects such as suppressed blood counts and neurologic problems were significantly worse for the group receiving abdominal chemotherapy, and they reported poorer quality of life during their treatment. Patients with adhesions or surgical complications, poor kidney function, and those who have had the left side of their colon removed during surgery are not good candidates for IP chemotherapy. Only 86 of the 205 patients enrolled for the abdominal therapy were able to complete the course.